News about Biotechnology

CGT Catapult to expand to Edinburgh BioQuarter to speed up product development

CGT Catapult to expand to Edinburgh BioQuarter to speed up product development

The Cell and Gene Therapy Catapult (CGT Catapult), an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation

Biotechnology | 02/07/2021 | By Darshana |  296

Alembic Pharma receives US FDA approval for generic Macrodantin capsules

Alembic Pharma receives US FDA approval for generic Macrodantin capsules

Alembic Pharmaceuticals Limited announced that it has received final approval from the US Food & Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for nitrofurantoin capsules, USP (Macrocrystals), 25 mg, 50 mg and 100 mg

Biotechnology | 01/07/2021 | By Darshana |  305

Dr. Reddy's Labs announces commercial launch of 2-DG

Dr. Reddy's Labs announces commercial launch of 2-DG

Dr Reddy's will supply to major government as well as private hospitals across India. In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India

Biotechnology | 28/06/2021 | By Darshana |  370

Biomerica inks pact with Canadian partner to distribute & market Helicobacter pylori test, hp+detect

Biomerica inks pact with Canadian partner to distribute & market Helicobacter pylori test, hp+detect

Biomerica announced that it has signed an exclusive five-year distribution agreement with a Canadian partner for the distribution and marketing of Biomerica's new and proprietary Helicobacter pylori test, called hp+detect

Biotechnology | 26/06/2021 | By Darshana |  252

Adroit Biomed Ltd develops Orally Dissolving Mini Effervescent Tablet to prevent, manage & recover from COVID 19

Adroit Biomed Ltd develops Orally Dissolving Mini Effervescent Tablet to prevent, manage & recover from COVID 19

Currently, the prevalent approach is to contain the spread of the virus by reducing interpersonal contacts and vaccination. An alternative strategy could involve the understanding of the molecular mechanisms underlying the known risk factors and to correct them, when possible, as a prevention/treatment of the disease

Biotechnology | 24/06/2021 | By Darshana |  451

Can-Fite BioPharma's A3AR ligand for use in treating ectopic fat accumulation receives Chinese patent

Can-Fite BioPharma's A3AR ligand for use in treating ectopic fat accumulation receives Chinese patent

Can-Fite BioPharma announced the Chinese National Intellectual Property Administration has issued a Notice of Allowance for its patent titled An A3 Adenosine Receptor Ligand for use in Treating Ectopic Fat Accumulation. This patent addresses the use of the A3 Adenosine Receptor (A3AR) ligand, the target receptor for Can-Fite's drug platform technology

Biotechnology | 20/06/2021 | By Darshana |  223

Researchers to have access to Cryo-EM facilities to combat new and emerging diseases

Researchers to have access to Cryo-EM facilities to combat new and emerging diseases

The Department of Science and Technology (DST) has announced that the researchers in the country would soon have access to four Cryogenic-Electron Microscopy (Cryo-EM) facilities paving the way towards establishment of leadership in structural biology, enzymology, and drug discovery to combat new and emerging diseases

Biotechnology | 18/06/2021 | By Darshana |  226

Debiopharm, Ubix Therapeutics ink research pact to develop new drug modality known as Antibody Degraducer Conjugates

Debiopharm, Ubix Therapeutics ink research pact to develop new drug modality known as Antibody Degraducer Conjugates

Debiopharm, a Swiss-based global biopharmaceutical company, and Ubix Therapeutics, a South Korea-based biotech company, announced their co-research agreement combining two novel proprietary technologies to specifically target cancer cells

Biotechnology | 17/06/2021 | By Darshana |  521

Zydus Cadila gets US FDA tentative marketing nod for epilepsy drug, brivaracetam

Zydus Cadila gets US FDA tentative marketing nod for epilepsy drug, brivaracetam

Zydus Cadila has received tentative approval from the US FDA to market brivaracetam tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg. Brivaracetam is used to treat partial-onset of seizures (epilepsy).

Biotechnology | 14/06/2021 | By Darshana |  235

Roche gets CE mark for SARS-CoV-2 Antigen Self Test Nasal for at-home testing

Roche gets CE mark for SARS-CoV-2 Antigen Self Test Nasal for at-home testing

Roche announced it has received CE mark for its SARS-CoV-2 Antigen Self Test Nasal for at-home testing. The test will be available in countries accepting the CE mark through pharmacies and other locations, in packs of five tests

Biotechnology | 09/06/2021 | By Darshana |  206

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members